Immix Biopharma, Inc. IMMX 深 沪
等待开盘 06-26 09:30:00 美东时间
9.76
-0.270
-2.69%
华盛通- 最 高10.50
- 今 开9.96
- 成交量 54.13万股
- 最 低 8.83
- 昨 收 10.03
- 总市值 1.02亿
- 52周最高 11.6099
- 市盈率 静 --
- 换手率 5.18%
- 52周最低 1.94
- 委 比 -29.03%
- 总股本 1045.15万
- 历史最高 11.6099
- 量 比 0.43
- 振 幅 16.65%
- 历史最低 0.68
- 每 手 1
- 风险率 2.86%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Immix Biopharma Analyst Bullish But Flags Safety, Adoption Questions
BofA Securities initiates Immix Biopharma with Buy rating, citing NXC-201's potential in AL amyloidosis and peak sales near $963 million.
06-19 01:38
Immix Biopharma Attends FDA CEO Forum in Washington DC
Immix Biopharma was selected by the FDA to attend a CEO forum focused on modernizing regulatory frameworks to support innovation and patient access to therapies.
2025-06-06 13:39
Immix Biopharma Announces Positive Results for NXC-201 at ASCO Oral Presentation, Enabling Pathway to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis
Immix Biopharma's NXC-201 shows 71% complete response rate in relapsed/refractory AL Amyloidosis, with no relapses or safety signals. Updated results to be presented at ASCO 2025 by Heather Landau, MD.
2025-05-22 20:02
Immix Biopharma to Host KOL Event to Discuss NXC-201 Clinical Data Presented at ASCO 2025 in relapsed/refractory AL Amyloidosis
Immix Biopharma will host a virtual KOL event on June 3, 2025, at 3:00pm ET, featuring experts Heather Landau, Shahzad Raza, and Jeffrey Zonder to discuss interim data from the NEXICART-2 Phase 1/2 trial of NXC-201 for relapsed/refractory AL Amyloidosis. A live Q&A will follow, and attendees can join via the provided link.
2025-05-21 20:03
Immix Biopharma Expands US Nexicart-2 Trial for AL Amyloidosis With 3 Clinical Sites
10:30 AM EDT, 08/28/2024 (MT Newswires) -- Immix Biopharma (IMMX) on Wednesday announced the inclusion of three more clinical trial sites in the US for its Nexicart-2 trial on relapsed/refractory AL amyloidosis. The newly added locations including Cleveland Clinic, UC Davis, and Sutter Health, featu...
2024-08-28 22:30
Immix Biopharma Expands U.S. Clinical Trial Sites For NEXICART-2 In Relapsed/Refractory AL Amyloidosis
Adding Cleveland Clinic, UC Davis, And Sutter Health; MSKCC Remains Lead Site, With Ex-U.S. Data Showing 92% Response Rate
2024-08-28 21:33
